Delivery Order SPE2DB22D2009-SPE2DB25FL8YR
- Not listed
- The Defense Logistics Agency awarded a $3,069.43 delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on September 5, 2025. This competitively awarded, non-set-aside contract has a ceiling value of $3,069.11 and is structured as a firm fixed price delivery order with an ultimate completion date of September 8, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Mounjaro 10 mg/0.5 ml pen injections valued at $7,989.68. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 12, 2025, with performance taking place at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to compete in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $4,401.61 to supply Mounjaro 2.5 mg/0.5 mL pen injections, with delivery to be completed by August 4, 2025. This competitively awarded, firm fixed-price delivery order was issued on August 1, 2025, with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,523.07 on August 8, 2025, for Mounjaro 7.5 mg/0.5 ml pen injections. This contract represents a firm fixed price delivery order with no set-aside designation, issued competitively under the agency's pharmaceutical procurement framework. The order is scheduled for completion by August 11, 2025, and will be fulfilled from the contractor's Conshohocken, Pennsylvania facility. This delivery order is issued...
- The Defense Logistics Agency awarded a $21,011.11 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Mounjaro 10 mg/0.5 ml pen injectors, with a completion date of September 9, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery order under AmerisourceBergen's larger indefinite delivery vehicle with DLA Troop Support Medical. The order will be fulfilled from the company's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $2,522.73 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen injections on September 24, 2025, with completion scheduled for September 25, 2025. This competitive award, placed with no set-aside designation, represents a firm fixed price transaction for pharmaceutical products to support federal medical procurement needs. The delivery will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $20,113.77 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pen injections (0.5 ml). The contract is set to be completed by July 31, 2025, with performance occurring at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This competitively awarded delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,228.25 delivery order on August 29, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pens with a completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning the award was competitively issued. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen injections with a contract ceiling value of $47,883.19. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and is scheduled for completion by August 7, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters location. This...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FL8YRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,541.93 to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections on April 24, 2025, with completion expected by April 25, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded pharmaceutical supply under the company's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. Mounjaro, a diabetes medication, aligns with the therapeutic scope of the underlying contract, which encompasses specialty medications, brand-name and generic drugs, vaccines, and other critical medical commodities to serve the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 4/24/25 |